Mass General Brigham’s Jounce Therapeutics JNCE Stock Holding History
Bought
Maintained
Sold
Other funds holding JNCE
Mass General Brigham's JNCE Position: Q2 2022 in Review
Mass General Brigham sold out of Jounce Therapeutics (JNCE) in Q2 2022, closing a stake of 20,957 shares — an estimated $142K sold.
Mass General Brigham first reported a position in JNCE in Q2 2021 and held it in 2 quarters. The position peaked at $142K in Q1 2022. 102 funds tracked by Wall St. Rank hold JNCE as of Q2 2022.
- Mass General Brigham reported no remaining Jounce Therapeutics position as of Q2 2022 after selling out during the quarter.
- Mass General Brigham sold 20,957 Jounce Therapeutics shares in Q2 2022, an estimated $142K.
- Mass General Brigham first reported a position in Jounce Therapeutics in Q2 2021 and held it in 2 quarters.
- Mass General Brigham's Jounce Therapeutics position peaked at $142K in Q1 2022.
- 102 funds tracked by Wall St. Rank held Jounce Therapeutics as of Q2 2022.
Based on Mass General Brigham's 13F filing for Q2 2022, filed 27 Jul 2022.